Europe Neurodegenerative Disease Market Size, Share & Trends Analysis Report By Disease Indication (Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease, Others), By Drug Type (Immunomodulator, Vesicular Monoamine Transporter 2 (VMAT2), Others), By Routes of Administration (Oral, Intravenous (IV) delivery, Others) and By Country (U.K., Germany, France, Spain, Italy, Russia, Nordic, Benelux, Rest of Europ) Forecasts, 2026-2034

Market Overview

The Europe neurodegenerative disease market size was valued at USD 16.63 billion in 2025 and is estimated to grow from USD 17.68 billion in 2026 to reach USD 28.45 billion by 2034, growing at a CAGR of 6.31% during the forecast period 2026–2034.

In most cases, neurodegenerative disorders are characterised by gradual nerve cell degeneration that can occur in a variety of locations across the body. Loss of memory and cognitive control are potential outcomes of a number of conditions, including Alzheimer's disease, Parkinson's disease, attention deficit hyperactivity disorder (ADHD), and amyotrophic lateral sclerosis (ALS).

Although there are very few diseases that can be cured, the pharmaceutical industry has developed a variety of treatments throughout the years that aim to alleviate the symptoms of neurodegenerative ailments.

Neurodegenerative disorders are a varied group of ailments defined by the gradual degradation of the function and structure of the central nervous system or peripheral nervous system. Neurodegenerative disorders, including Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, and Huntington's disease, have been rising globally. Thus, the growing burden of this condition is the key driver driving the market expansion, adding to it the expanding elderly population. According to NIH, nearly 1.2 million people in the United States will have Parkinson's disease by 2030. In the United States, it is the second most frequent neurodegenerative disorder.

Furthermore, according to Alzheimer's Disease International, more than 50 million adults with dementia globally in 2020. This number is anticipated to be more than double every two decades, reaching 82 million in 2030 and 152 million in 2050. Additionally, much of the increase will be in emerging countries. About 60% of persons with dementia reside in poor and middle-income nations, but by 2050, this will climb to 71%. The fastest rise in the senior population has happened in China, India, and South Asian and western Pacific countries. Thus, the growing burden of dementia is likely to enhance the market growth in the approaching years.

Europe Neurodegenerative Disease Market Segmental Analysis

By Disease Indication

The Europe neurodegenerative disease market is segmented by disease indication into multiple sclerosis, Parkinson's disease, Alzheimer's disease, and others. Multiple sclerosis remains an important treatment area because patients generally require prolonged disease management and regular monitoring, while continued development of disease-modifying therapies is broadening treatment options. Parkinson's disease is also generating sustained demand as Europe's aging population increases the number of individuals requiring management of progressive movement and neurological symptoms. Alzheimer's disease represents another major area of focus, supported by increasing attention toward cognitive decline, earlier diagnosis, and long-term patient care. Improvements in neurological assessment and access to specialist healthcare are helping strengthen diagnosis and treatment across European countries.

The others category covers neurodegenerative conditions outside the major indications and contributes additional demand for specialized diagnosis and therapeutic management. Growing investment in neurological research, improvements in diagnostic technologies, and increasing awareness of neurological disorders are creating opportunities across this broader category. Europe's established healthcare infrastructure, specialist networks, and expanding pharmaceutical research ecosystem support the development and adoption of advanced treatments. At the same time, differences in reimbursement policies, treatment costs, healthcare access, and national regulatory frameworks can influence the pace of adoption across individual European markets.

Request Customizationto receive a tailored report.

By Drug Type

The Europe neurodegenerative disease market is categorized by drug type into immunomodulator, vesicular monoamine transporter 2 (VMAT2), and others. Immunomodulators are particularly relevant to neurological conditions in which immune-system activity contributes to disease mechanisms or progression, creating demand for therapies capable of modifying abnormal immune responses. VMAT2-targeted therapies represent a specialized drug category associated with neurotransmitter regulation and the management of certain neurological and movement-related symptoms. The availability of disease-specific treatment options, growing clinical understanding of neurological pathways, and continued pharmaceutical research are supporting the development of these drug categories across Europe.

The others segment includes therapeutic approaches that do not fall within immunomodulators or VMAT2-targeted medicines. These treatments may be used to manage symptoms, address specific neurological mechanisms, or support disease control depending on the patient's condition. Pharmaceutical companies are increasingly investigating new targets and treatment approaches, which could broaden the available therapeutic landscape. In Europe, adoption is influenced by clinical guidelines, regulatory approvals, reimbursement arrangements, medicine pricing, physician preferences, and patient access. Well-developed healthcare systems and established pharmaceutical research capabilities provide a favorable environment for the introduction of innovative neurological therapies.

By Routes of Administration

The Europe neurodegenerative disease market is divided by routes of administration into oral, intravenous (IV) delivery, and others. Oral administration remains an important route because tablets and capsules provide convenience for patients undergoing long-term treatment and can often be incorporated into outpatient care. This route can reduce the need for repeated visits to healthcare facilities and simplify treatment routines for patients and caregivers. Intravenous (IV) delivery is used for therapies requiring direct bloodstream administration, controlled dosing, or professional supervision. The presence of advanced hospitals, specialist neurological centers, and infusion facilities across Europe supports the use of IV therapies where clinically appropriate.

The others category includes alternative administration methods that may be selected according to the formulation, therapeutic characteristics, disease severity, or individual patient requirements. Developments in drug-delivery technologies are encouraging the use of formulations designed to improve drug absorption, maintain therapeutic exposure, and enhance treatment convenience. The adoption of different administration routes across Europe is shaped by healthcare infrastructure, treatment affordability, regulatory requirements, reimbursement policies, and physician preferences. As pharmaceutical developers introduce more specialized neurological therapies, the availability of multiple administration options is expected to remain important for personalized and long-term disease management.

Speak to an Analystto discuss market opportunities.

Europe Neurodegenerative Disease Market Regional Analysis

The income generated in Europe in 2021 was estimated to be 11,500 million USD, making it the second-largest market. It is anticipated that by the year 2030, its value would have increased to USD 15,675 million, representing a CAGR of 3.5% for the time being analysed. Germany is home to a sizable number of worldwide enterprises engaged in the research and development of treatments for neurodegenerative diseases. Additionally, disease awareness and a rise in the number of medication releases by major pharmaceutical firms in the nation are likely to boost the market that has been researched. This is due to the growing incidence of these conditions.

In addition, it is anticipated that the number of individuals living with dementia would increase over the next several years, which would have a beneficial influence on the market. According to the Alzheimer Europe 2019 study, the number of persons living in Germany who were diagnosed with dementia in 2018 was around 1,585,166, and it is estimated that this figure would climb to 2,748,178 by the year 2050. In a similar vein, the percentage of the general population that is affected by dementia is projected to rise to 3.43% in 2050 from 1.91% in 2018.

List of Key and Emerging Players in Europe Neurodegenerative Disease Market